PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
Sharlene Gill(Deventer Ziekenhuis), Malcolm J. Moore(University Health Network), Helene Grassin(BC Cancer Agency), Pablo Cano(BC Cancer Agency), Sukhbinder Dhesy‐Thind(BC Cancer Agency), Paweł Zalewski(Medical University of Warsaw), C. Cripps(Canadian Partnership Against Cancer), Wendy Yin Han Lam(BC Cancer Agency), John A. Stewart(Centers for Disease Control and Prevention), Muhammad Zulfiqar(BC Cancer Agency), Yoo‐Joung Ko(Sunnybrook Health Science Centre), Scot Dowden, Annie Beaudoin(BC Cancer Agency), Thuan Do(BC Cancer Agency)
Cited by 291
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k